Science

Mario Balsa: Real-world Comparison in Advanced HCC – Atezolizumab + Bevacizumab vs Tremelimumab + Durvalumab

Mario Balsa/X

Jun 25, 2025, 09:27

Mario Balsa: Real-world Comparison in Advanced HCC – Atezolizumab + Bevacizumab vs Tremelimumab + Durvalumab

Mario Balsa, Medical Oncology resident at ICO, shared a post on X:

“Real-world comparison in advanced HCC: Atezolizumab +Bevacizumab vs Tremelimumab +Durvalumab

>2,300 patients from TriNetX
No significant OS difference

Sometimes, the real drama lies in the tie

Congrats Andrea Casadei Gardini and the team!”

Title: Comparative Effectiveness of Atezolizumab Plus Bevacizumab Versus Tremelimumab Plus Durvalumab in Patients with Hepatocellular Carcinoma (HCC) in a Real-World Setting

Authors: Federica Lo Prinzi, Federico Rossari, Marianna Silletta, Silvia Camera, Silvia Foti, Mara Persano, Francesco Vitiello, Emanuela Di Giacomo, Mariam Grazia Polito, Margherita Rimini and Andrea Casadei-Gardini

You can read the Full Article on Springer Nature

Mario Balsa: Real-world Comparison in Advanced HCC - Atezolizumab + Bevacizumab vs Tremelimumab + Durvalumab

More posts featuring Mario Balsa.

atezolizumab Bevacizumab cancer Durvalumab Emanuela Di Giacomo Federica Lo Prinzi Federico Rossari Francesco Vitiello HCC hepatocellular carcinoma Mara Persano Margherita Rimini Mariam Grazia Polito Marianna Silletta Mario Balsa OncoDaily Oncology Silvia Camera Silvia Foti Tremelimumab

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data

New Paper Alert: Breakthrough iNKT Cell Therapy Achieves Complete Remission in Metastatic Germ Cell Tumor

"God Invented This" - Pat Soon-Shiong on Cancer Discovery

Yüksel Ürün: Science Is Better When It’s Shared

Oliver Bogler: Grant Tips